Abstract
Aim and Background: Amytriptiline (AMY), an antidepressant, is used in the treatment of neuropathic pain. However, with limited therapeutic benefits and side effects of AMY, it is not helpful to the majority of the neuropathic pain patients. Gallic acid (GA) is a polyphenolic product with potential antioxidant effects, useful in neuropathic pain.
Objective: The purpose of the study was to investigate the improved neuropathic pain relief with GA in combination with AMY in rats.
Methods: Partial sciatic nerve ligation (PSNL) method is used for neuropathic pain induction in rats. The rats were randomly divided into 6 groups (n = 8), and treated with drugs or vehicle once daily for 15 days after the pain induction. The first group served as Normal control and received normal saline (p.o), the second group served as Sham Control and received Normal Saline (p.o), the third group served as Surgery Control and received normal saline (p.o), the fourth group received AMY (25mg/kg, p.o), while the fifth group received GA (100mg/kg,p.o), and the sixth group received both AMY and GA. Further behavioural studies for pain were carried out on days 1,4,7,10,13,16,19 and 22. Histological studies of sciatic nerves were carried out on days 1, 15 and 22, and on the 22nd day, all the remaining animals were sacrificed for the biochemical estimations of the sciatic nerve tissues.
Results: GA attenuates neuropathic pain better in combination with AMY by ameliorating the behavioral, biochemical and histopathological signs and symptoms. This resultant effect is due to its antioxidant, antinociceptive and anti-inflammatory actions. It also potentiates AMY antinociceptive and antioxidant effects when given in combination in a continuous treatment.
Conclusion: The results suggest that GA in combination with AMYattenuated the neuropathic pain. Hence, the use of GA as an adjunctive with AMY in the neuropathic pain will be more therapeutically beneficial; further studies on patients to confirm the results are warranted.
Keywords: Amytriptiline, gallic acid, neuropathic pain, partial sciatic nerve ligation (PSNL), behavioral studies, sciatic nerve tissues.
Graphical Abstract
The Natural Products Journal
Title:Gallic Acid Improved Amytryptiline Effect in Neuropathic Pain Induced by Partial Sciatic Nerve Ligation (PSNL) in Rats
Volume: 11 Issue: 5
Author(s): Prasad Neerati*Vinay Enumula
Affiliation:
- DMPK & Clinical Pharmacology, University College of Pharmaceutical Sciences, Kakatiya University, Telangana, Warangal 506002,India
Keywords: Amytriptiline, gallic acid, neuropathic pain, partial sciatic nerve ligation (PSNL), behavioral studies, sciatic nerve tissues.
Abstract:
Aim and Background: Amytriptiline (AMY), an antidepressant, is used in the treatment of neuropathic pain. However, with limited therapeutic benefits and side effects of AMY, it is not helpful to the majority of the neuropathic pain patients. Gallic acid (GA) is a polyphenolic product with potential antioxidant effects, useful in neuropathic pain.
Objective: The purpose of the study was to investigate the improved neuropathic pain relief with GA in combination with AMY in rats.
Methods: Partial sciatic nerve ligation (PSNL) method is used for neuropathic pain induction in rats. The rats were randomly divided into 6 groups (n = 8), and treated with drugs or vehicle once daily for 15 days after the pain induction. The first group served as Normal control and received normal saline (p.o), the second group served as Sham Control and received Normal Saline (p.o), the third group served as Surgery Control and received normal saline (p.o), the fourth group received AMY (25mg/kg, p.o), while the fifth group received GA (100mg/kg,p.o), and the sixth group received both AMY and GA. Further behavioural studies for pain were carried out on days 1,4,7,10,13,16,19 and 22. Histological studies of sciatic nerves were carried out on days 1, 15 and 22, and on the 22nd day, all the remaining animals were sacrificed for the biochemical estimations of the sciatic nerve tissues.
Results: GA attenuates neuropathic pain better in combination with AMY by ameliorating the behavioral, biochemical and histopathological signs and symptoms. This resultant effect is due to its antioxidant, antinociceptive and anti-inflammatory actions. It also potentiates AMY antinociceptive and antioxidant effects when given in combination in a continuous treatment.
Conclusion: The results suggest that GA in combination with AMYattenuated the neuropathic pain. Hence, the use of GA as an adjunctive with AMY in the neuropathic pain will be more therapeutically beneficial; further studies on patients to confirm the results are warranted.
Export Options
About this article
Cite this article as:
Neerati Prasad *, Enumula Vinay , Gallic Acid Improved Amytryptiline Effect in Neuropathic Pain Induced by Partial Sciatic Nerve Ligation (PSNL) in Rats, The Natural Products Journal 2021; 11 (5) . https://dx.doi.org/10.2174/2210315510999200723162912
DOI https://dx.doi.org/10.2174/2210315510999200723162912 |
Print ISSN 2210-3155 |
Publisher Name Bentham Science Publisher |
Online ISSN 2210-3163 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Tumor Invasion and Oxidative Stress: Biomarkers and Therapeutic Strategies
Current Molecular Medicine Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Berberine Exhibits Antitumor Effects in Human Ovarian Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Chemo-Radiation Association in Head and Neck Squamous Cell Carcinoma: Evidences and Criticisms
Current Drug Therapy Esophagogastric Cancer: Integration of Targeted Therapies into Systemic Chemotherapy
Current Cancer Drug Targets Application of Nanotechnology in the Treatment and Diagnosis of Gastrointestinal Cancers: Review of Recent Patents
Recent Patents on Anti-Cancer Drug Discovery Statins and Alkylphospholipids as New Anticancer Agents Targeting Lipid Metabolism
Anti-Cancer Agents in Medicinal Chemistry Clinical Science of Calcium Channel Blocker to Inhibit Hypertensive Vascular Injury
Current Hypertension Reviews High Throughput Screening of Normal and Neoplastic Tissue Samples
Combinatorial Chemistry & High Throughput Screening Perspectives of Benzimidazole Derivatives as Anticancer Agents in the New Era
Anti-Cancer Agents in Medicinal Chemistry Sphingosine Kinases Signalling in Carcinogenesis
Mini-Reviews in Medicinal Chemistry Discussion on the Structural Modification and Anti-tumor Activity of Flavonoids
Current Topics in Medicinal Chemistry Zoledronate Induced Hypocalcemia and Hypophosphatemia in Osteoporosis: A Cause of Concern
Current Drug Safety Angiogenesis Markers in Gynecological Tumors and Patents for Anti- Angiogenic Approach: Review
Recent Patents on Anti-Cancer Drug Discovery Growth Factor Signaling and Resistance to Cancer Chemotherapy
Current Topics in Medicinal Chemistry Recent Advances in Characterizing Natural Products that Regulate Autophagy
Anti-Cancer Agents in Medicinal Chemistry Interrelationships of Circulating Tumor Cells with Metastasis and Thrombosis: Role of MicroRNAs
Current Pharmaceutical Design DYRK1A Kinase Inhibitors with Emphasis on Cancer
Mini-Reviews in Medicinal Chemistry Infrared Microspectroscopy Applications - Review
Current Analytical Chemistry An Expanding Appreciation of the Role Chemokine Receptors Play in Cancer Progression
Current Pharmaceutical Design